Although antibodies targeting CTLA-4 and PD-1/PD-L1 represent a major breakthrough in cancer immunotherapy, application of checkpoint inhibitors in certain tumors have not led to significant tumor regression. This evidence concerns the gene CTLA4 and neoplasm.